Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Food allergens are typically naturally occurring proteins or glycoproteins found in food sources that elicit an abnormal, hypersensitive immune response in sensitized individuals, most commonly through an Immunoglobulin E (IgE)-mediated pathway [1][2]. These molecules often possess specific structural features, such as resistance to heat and proteolytic digestion, which allow them to reach the intestinal mucosa intact and trigger an immune response [3]. When these allergens cross-link IgE bound to high-affinity receptors on mast cells and basophils, they induce the rapid release of inflammatory mediators like histamine, leading to symptoms that can range from mild cutaneous reactions to fatal systemic anaphylaxis [2][6]. From a therapeutic perspective, food allergens are unique because they are both the causative agents of disease and the active components in allergen-specific immunotherapy (AIT). Modern pharmaceutical interventions, such as FDA-approved oral immunotherapy for peanut allergy, utilize standardized doses of the allergen to gradually increase the patient's threshold for reaction and induce clinical desensitization [4][5]. Additionally, monoclonal antibodies like Omalizumab are used to sequester IgE, preventing its interaction with the allergen and thereby increasing the safety margin for patients at risk of accidental exposure or those undergoing immunotherapy [7]. [1] NIH: National Institute of Allergy and Infectious Diseases. [2] StatPearls: Food Allergy. [3] WHO/IUIS Allergen Nomenclature Database. [4] FDA: Palforzia Prescribing Information. [5] PubMed: PMID 30444330. [6] PubMed: PMID 29306565. [7] PubMed: PMID 38407335.
In therapeutic contexts like Oral Immunotherapy (OIT), the allergen acts as an immunomodulator to induce desensitization by shifting the immune response from a Th2/IgE-mediated profile to a Th1/IgG4-mediated profile and increasing regulatory T cell (Treg) activity [4][5].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Food allergen.